aluates Reports

$ 0.0

Automative

Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-26L4878

Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Insights Forecast to 2028

BUY CHAPTERS

Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Research Report 2025

Code: QYRE-Auto-26L4878

Report

July 2025

Pages:93

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Advenchen Laboratories

Amgen Inc

ArQule Inc

Santa Cruz Biotechnology

Astrazeneca plc

AVEO Pharmaceuticals

Batu Biologics

Boehringer Ingelheim

Bristol Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eisai Co Ltd

Eli Lilly and Company

Hutchison MediPharma

Novartis

Principia Biopharma

Vichem Chemie Research

Fibroblast Growth Factor Receptor 2 Inhibitor Market Size

The global market for Fibroblast Growth Factor Receptor 2 Inhibitor was valued at US$ 2274 million in the year 2024 and is projected to reach a revised size of US$ 3581 million by 2031, growing at a CAGR of 6.8% during the forecast period.

Fibroblast Growth Factor Receptor 2 Inhibitor Market

Fibroblast growth factor 2 (FGF2) belongs to the family of fibroblast growth factors (FGFs), and is a potent inducer involved in the processes of proliferation and differentiation of a wide variety of cells derived from mesoderm and neuroectoderm.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Fibroblast Growth Factor Receptor 2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Fibroblast Growth Factor Receptor 2 Inhibitor.

The Fibroblast Growth Factor Receptor 2 Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Fibroblast Growth Factor Receptor 2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Fibroblast Growth Factor Receptor 2 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Fibroblast Growth Factor Receptor 2 Inhibitor Market Report

Report Metric	Details
Report Name	Fibroblast Growth Factor Receptor 2 Inhibitor Market
Accounted market size in year	US$ 2274 million
Forecasted market size in 2031	US$ 3581 million
CAGR	6.8%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	ASP-5878 AZD-4547 BAY-1163877 CPL-043 Debio-1347 EDP-317 Others
Segment by Application	Clinic Hospital Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Fibroblast Growth Factor Receptor 2 Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Fibroblast Growth Factor Receptor 2 Inhibitor Market growing?

Ans: The Fibroblast Growth Factor Receptor 2 Inhibitor Market witnessing a CAGR of 6.8% during the forecast period 2025-2031.

What is the Fibroblast Growth Factor Receptor 2 Inhibitor Market size in 2031?

Ans: The Fibroblast Growth Factor Receptor 2 Inhibitor Market size in 2031 will be US$ 3581 million.

Who are the main players in the Fibroblast Growth Factor Receptor 2 Inhibitor Market report?

Ans: The main players in the Fibroblast Growth Factor Receptor 2 Inhibitor Market are Advenchen Laboratories, Amgen, ArQule, Santa Cruz Biotechnology, AstraZeneca, AVEO Pharmaceuticals, Batu Biologics, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celon Pharma, Debiopharm International, Eddingpharm, Eisai, Eli Lilly and Company, Hutchison MediPharma, Novartis, Principia Biopharma, Vichem Chemie Research

What are the Application segmentation covered in the Fibroblast Growth Factor Receptor 2 Inhibitor Market report?

Ans: The Applications covered in the Fibroblast Growth Factor Receptor 2 Inhibitor Market report are Clinic, Hospital, Others

What are the Type segmentation covered in the Fibroblast Growth Factor Receptor 2 Inhibitor Market report?

Ans: The Types covered in the Fibroblast Growth Factor Receptor 2 Inhibitor Market report are ASP-5878, AZD-4547, BAY-1163877, CPL-043, Debio-1347, EDP-317, Others

Recommended Reports

Cancer Targeted Therapy

Fibrosis & Inflammation

Diagnostics & Testing

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 ASP-5878

1.2.3 AZD-4547

1.2.4 BAY-1163877

1.2.5 CPL-043

1.2.6 Debio-1347

1.2.7 EDP-317

1.2.8 Others

1.3 Market by Application

1.3.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Clinic

1.3.3 Hospital

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Perspective (2020-2031)

2.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Growth Trends by Region

2.2.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Region (2020-2025)

2.2.3 Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Region (2026-2031)

2.3 Fibroblast Growth Factor Receptor 2 Inhibitor Market Dynamics

2.3.1 Fibroblast Growth Factor Receptor 2 Inhibitor Industry Trends

2.3.2 Fibroblast Growth Factor Receptor 2 Inhibitor Market Drivers

2.3.3 Fibroblast Growth Factor Receptor 2 Inhibitor Market Challenges

2.3.4 Fibroblast Growth Factor Receptor 2 Inhibitor Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Revenue

3.1.1 Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Revenue (2020-2025)

3.1.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Players (2020-2025)

3.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue

3.4 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Concentration Ratio

3.4.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in 2024

3.5 Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor Head office and Area Served

3.6 Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor, Product and Application

3.7 Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Fibroblast Growth Factor Receptor 2 Inhibitor Breakdown Data by Type

4.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Type (2020-2025)

4.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Type (2026-2031)

5 Fibroblast Growth Factor Receptor 2 Inhibitor Breakdown Data by Application

5.1 Global Fibroblast Growth Factor Receptor 2 Inhibitor Historic Market Size by Application (2020-2025)

5.2 Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2020-2031)

6.2 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025)

6.4 North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2020-2031)

7.2 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025)

7.4 Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2020-2031)

8.2 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2020-2025)

8.4 Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2020-2031)

9.2 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025)

9.4 Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (2020-2031)

10.2 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025)

10.4 Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Advenchen Laboratories

11.1.1 Advenchen Laboratories Company Details

11.1.2 Advenchen Laboratories Business Overview

11.1.3 Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.1.4 Advenchen Laboratories Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.1.5 Advenchen Laboratories Recent Development

11.2 Amgen

11.2.1 Amgen Company Details

11.2.2 Amgen Business Overview

11.2.3 Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.2.4 Amgen Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.2.5 Amgen Recent Development

11.3 ArQule

11.3.1 ArQule Company Details

11.3.2 ArQule Business Overview

11.3.3 ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.3.4 ArQule Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.3.5 ArQule Recent Development

11.4 Santa Cruz Biotechnology

11.4.1 Santa Cruz Biotechnology Company Details

11.4.2 Santa Cruz Biotechnology Business Overview

11.4.3 Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.4.4 Santa Cruz Biotechnology Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.4.5 Santa Cruz Biotechnology Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Details

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.5.4 AstraZeneca Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.5.5 AstraZeneca Recent Development

11.6 AVEO Pharmaceuticals

11.6.1 AVEO Pharmaceuticals Company Details

11.6.2 AVEO Pharmaceuticals Business Overview

11.6.3 AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.6.4 AVEO Pharmaceuticals Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.6.5 AVEO Pharmaceuticals Recent Development

11.7 Batu Biologics

11.7.1 Batu Biologics Company Details

11.7.2 Batu Biologics Business Overview

11.7.3 Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.7.4 Batu Biologics Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.7.5 Batu Biologics Recent Development

11.8 Boehringer Ingelheim

11.8.1 Boehringer Ingelheim Company Details

11.8.2 Boehringer Ingelheim Business Overview

11.8.3 Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.8.4 Boehringer Ingelheim Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.8.5 Boehringer Ingelheim Recent Development

11.9 Bristol-Myers Squibb Company

11.9.1 Bristol-Myers Squibb Company Company Details

11.9.2 Bristol-Myers Squibb Company Business Overview

11.9.3 Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.9.4 Bristol-Myers Squibb Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.9.5 Bristol-Myers Squibb Company Recent Development

11.10 Celon Pharma

11.10.1 Celon Pharma Company Details

11.10.2 Celon Pharma Business Overview

11.10.3 Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.10.4 Celon Pharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.10.5 Celon Pharma Recent Development

11.11 Debiopharm International

11.11.1 Debiopharm International Company Details

11.11.2 Debiopharm International Business Overview

11.11.3 Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.11.4 Debiopharm International Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.11.5 Debiopharm International Recent Development

11.12 Eddingpharm

11.12.1 Eddingpharm Company Details

11.12.2 Eddingpharm Business Overview

11.12.3 Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.12.4 Eddingpharm Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.12.5 Eddingpharm Recent Development

11.13 Eisai

11.13.1 Eisai Company Details

11.13.2 Eisai Business Overview

11.13.3 Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.13.4 Eisai Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.13.5 Eisai Recent Development

11.14 Eli Lilly and Company

11.14.1 Eli Lilly and Company Company Details

11.14.2 Eli Lilly and Company Business Overview

11.14.3 Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.14.4 Eli Lilly and Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.14.5 Eli Lilly and Company Recent Development

11.15 Hutchison MediPharma

11.15.1 Hutchison MediPharma Company Details

11.15.2 Hutchison MediPharma Business Overview

11.15.3 Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.15.4 Hutchison MediPharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.15.5 Hutchison MediPharma Recent Development

11.16 Novartis

11.16.1 Novartis Company Details

11.16.2 Novartis Business Overview

11.16.3 Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.16.4 Novartis Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.16.5 Novartis Recent Development

11.17 Principia Biopharma

11.17.1 Principia Biopharma Company Details

11.17.2 Principia Biopharma Business Overview

11.17.3 Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.17.4 Principia Biopharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.17.5 Principia Biopharma Recent Development

11.18 Vichem Chemie Research

11.18.1 Vichem Chemie Research Company Details

11.18.2 Vichem Chemie Research Business Overview

11.18.3 Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Introduction

11.18.4 Vichem Chemie Research Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

11.18.5 Vichem Chemie Research Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Advenchen Laboratories

Amgen Inc

ArQule Inc

Santa Cruz Biotechnology

Astrazeneca plc

AVEO Pharmaceuticals

Batu Biologics

Boehringer Ingelheim

Bristol Myers Squibb Company

Celon Pharma

Debiopharm International

Eddingpharm

Eisai Co Ltd

Eli Lilly and Company

Hutchison MediPharma

Novartis

Principia Biopharma

Vichem Chemie Research

List of Tables

Table 1. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of ASP-5878

Table 3. Key Players of AZD-4547

Table 4. Key Players of BAY-1163877

Table 5. Key Players of CPL-043

Table 6. Key Players of Debio-1347

Table 7. Key Players of EDP-317

Table 8. Key Players of Others

Table 9. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 11. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2020-2025) & (US$ Million)

Table 12. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2020-2025)

Table 13. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 14. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2026-2031)

Table 15. Fibroblast Growth Factor Receptor 2 Inhibitor Market Trends

Table 16. Fibroblast Growth Factor Receptor 2 Inhibitor Market Drivers

Table 17. Fibroblast Growth Factor Receptor 2 Inhibitor Market Challenges

Table 18. Fibroblast Growth Factor Receptor 2 Inhibitor Market Restraints

Table 19. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue by Players (2020-2025) & (US$ Million)

Table 20. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Players (2020-2025)

Table 21. Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor as of 2024)

Table 22. Ranking of Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Companies by Revenue (US$ Million) in 2024

Table 23. Global 5 Largest Players Market Share by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue (CR5 and HHI) & (2020-2025)

Table 24. Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor, Headquarters and Area Served

Table 25. Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor, Product and Application

Table 26. Global Key Players of Fibroblast Growth Factor Receptor 2 Inhibitor, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Type (2020-2025) & (US$ Million)

Table 29. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Type (2020-2025)

Table 30. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 31. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Type (2026-2031)

Table 32. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Application (2020-2025) & (US$ Million)

Table 33. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Application (2020-2025)

Table 34. Global Fibroblast Growth Factor Receptor 2 Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 35. Global Fibroblast Growth Factor Receptor 2 Inhibitor Revenue Market Share by Application (2026-2031)

Table 36. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 38. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 39. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 41. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 42. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 43. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2020-2025) & (US$ Million)

Table 44. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Region (2026-2031) & (US$ Million)

Table 45. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 47. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 48. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2020-2025) & (US$ Million)

Table 50. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Country (2026-2031) & (US$ Million)

Table 51. Advenchen Laboratories Company Details

Table 52. Advenchen Laboratories Business Overview

Table 53. Advenchen Laboratories Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 54. Advenchen Laboratories Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 55. Advenchen Laboratories Recent Development

Table 56. Amgen Company Details

Table 57. Amgen Business Overview

Table 58. Amgen Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 59. Amgen Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 60. Amgen Recent Development

Table 61. ArQule Company Details

Table 62. ArQule Business Overview

Table 63. ArQule Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 64. ArQule Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 65. ArQule Recent Development

Table 66. Santa Cruz Biotechnology Company Details

Table 67. Santa Cruz Biotechnology Business Overview

Table 68. Santa Cruz Biotechnology Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 69. Santa Cruz Biotechnology Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 70. Santa Cruz Biotechnology Recent Development

Table 71. AstraZeneca Company Details

Table 72. AstraZeneca Business Overview

Table 73. AstraZeneca Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 74. AstraZeneca Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 75. AstraZeneca Recent Development

Table 76. AVEO Pharmaceuticals Company Details

Table 77. AVEO Pharmaceuticals Business Overview

Table 78. AVEO Pharmaceuticals Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 79. AVEO Pharmaceuticals Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 80. AVEO Pharmaceuticals Recent Development

Table 81. Batu Biologics Company Details

Table 82. Batu Biologics Business Overview

Table 83. Batu Biologics Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 84. Batu Biologics Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 85. Batu Biologics Recent Development

Table 86. Boehringer Ingelheim Company Details

Table 87. Boehringer Ingelheim Business Overview

Table 88. Boehringer Ingelheim Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 89. Boehringer Ingelheim Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 90. Boehringer Ingelheim Recent Development

Table 91. Bristol-Myers Squibb Company Company Details

Table 92. Bristol-Myers Squibb Company Business Overview

Table 93. Bristol-Myers Squibb Company Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 94. Bristol-Myers Squibb Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 95. Bristol-Myers Squibb Company Recent Development

Table 96. Celon Pharma Company Details

Table 97. Celon Pharma Business Overview

Table 98. Celon Pharma Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 99. Celon Pharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 100. Celon Pharma Recent Development

Table 101. Debiopharm International Company Details

Table 102. Debiopharm International Business Overview

Table 103. Debiopharm International Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 104. Debiopharm International Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 105. Debiopharm International Recent Development

Table 106. Eddingpharm Company Details

Table 107. Eddingpharm Business Overview

Table 108. Eddingpharm Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 109. Eddingpharm Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 110. Eddingpharm Recent Development

Table 111. Eisai Company Details

Table 112. Eisai Business Overview

Table 113. Eisai Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 114. Eisai Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 115. Eisai Recent Development

Table 116. Eli Lilly and Company Company Details

Table 117. Eli Lilly and Company Business Overview

Table 118. Eli Lilly and Company Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 119. Eli Lilly and Company Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 120. Eli Lilly and Company Recent Development

Table 121. Hutchison MediPharma Company Details

Table 122. Hutchison MediPharma Business Overview

Table 123. Hutchison MediPharma Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 124. Hutchison MediPharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 125. Hutchison MediPharma Recent Development

Table 126. Novartis Company Details

Table 127. Novartis Business Overview

Table 128. Novartis Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 129. Novartis Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 130. Novartis Recent Development

Table 131. Principia Biopharma Company Details

Table 132. Principia Biopharma Business Overview

Table 133. Principia Biopharma Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 134. Principia Biopharma Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 135. Principia Biopharma Recent Development

Table 136. Vichem Chemie Research Company Details

Table 137. Vichem Chemie Research Business Overview

Table 138. Vichem Chemie Research Fibroblast Growth Factor Receptor 2 Inhibitor Product

Table 139. Vichem Chemie Research Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025) & (US$ Million)

Table 140. Vichem Chemie Research Recent Development

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

Table 144. Authors List of This Report

List of Figures

Figure 1. Fibroblast Growth Factor Receptor 2 Inhibitor Picture

Figure 2. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Type: 2024 VS 2031

Figure 4. ASP-5878 Features

Figure 5. AZD-4547 Features

Figure 6. BAY-1163877 Features

Figure 7. CPL-043 Features

Figure 8. Debio-1347 Features

Figure 9. EDP-317 Features

Figure 10. Others Features

Figure 11. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size by Application (2020-2031) & (US$ Million)

Figure 12. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Application: 2024 VS 2031

Figure 13. Clinic Case Studies

Figure 14. Hospital Case Studies

Figure 15. Others Case Studies

Figure 16. Fibroblast Growth Factor Receptor 2 Inhibitor Report Years Considered

Figure 17. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region: 2024 VS 2031

Figure 20. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Players in 2024

Figure 21. Global Top Fibroblast Growth Factor Receptor 2 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Fibroblast Growth Factor Receptor 2 Inhibitor as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Fibroblast Growth Factor Receptor 2 Inhibitor Revenue in 2024

Figure 23. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2020-2031)

Figure 25. United States Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2020-2031)

Figure 29. Germany Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Region (2020-2031)

Figure 37. China Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2020-2031)

Figure 45. Mexico Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Fibroblast Growth Factor Receptor 2 Inhibitor Market Share by Country (2020-2031)

Figure 49. Turkey Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Fibroblast Growth Factor Receptor 2 Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Advenchen Laboratories Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 53. Amgen Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 54. ArQule Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 55. Santa Cruz Biotechnology Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 56. AstraZeneca Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 57. AVEO Pharmaceuticals Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 58. Batu Biologics Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 59. Boehringer Ingelheim Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 61. Celon Pharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 62. Debiopharm International Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 63. Eddingpharm Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 64. Eisai Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 65. Eli Lilly and Company Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 66. Hutchison MediPharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 67. Novartis Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 68. Principia Biopharma Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 69. Vichem Chemie Research Revenue Growth Rate in Fibroblast Growth Factor Receptor 2 Inhibitor Business (2020-2025)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Fibroblast Growth Factor 2 FGF 2 Market Research Report 2025

Global Pan FGFR Inhibitors Market Research Report 2024

Global Fibroblast Growth Factor Receptor 2 Market Research Report 2025

Global Human Fibroblast Growth Factor 2 FGF2 Market Research Report 2024

Global Fibroblast Growth Factor Receptor 3 FGFR3 Antibody Market Research Report 2024

Global FGFR5 Antibody Market Research Report 2024

Global VEGFR 2 Inhibitor Market Research Report 2024

Global Human FGFR3 Fibroblast growth factor receptor Market Research Report 2024

Global Fibroblast Growth Factor 2 Market Research Report 2024

VEGF Inhibitor Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Fibroblast Activation Protein Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Fibroblast Growth Factor Kit Market Research Report 2024

Global Human Fibroblast Growth Factor Detection Kit Market Research Report 2025

Global Fibroblast Growth Factors FGF Market Research Report 2025

Global Human Fibroblast Growth Factor Market Research Report 2024

Global Epidermal Growth Factor Receptor EGFR Inhibitor Market Insights Forecast to 2030

Global Growth Factors and Cytokines Market Research Report 2024

Global Recombinant Human Fibroblast Growth Factor Market Research Report 2024

Global Epidermal Growth Factor Receptor Inhibitors Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions